Next-generation dual-action GLP-1 & GIP medical weight loss therapy in Nairobi. Achieve up to 20–22% weight reduction under comprehensive clinical supervision.
Modern prescription weight loss injections work by targeting hormones that regulate hunger, fullness, and metabolism. Tirzepatide (widely known under the brand name Tirzepatide (GLP-1 & GIP)) is an advanced dual-agonist medication targeting both GLP-1 and GIP receptors — available at Nairobi Bariatric Center under strict medical supervision following a full clinical consultation.
By activating two distinct metabolic pathways, dual-agonist Tirzepatide therapy has shown clinical trial weight loss of up to 20–22%, making it one of the most effective non-surgical interventions available today.
Synchronized GLP-1 & GIP metabolic regulation
"Working with Nairobi Bariatric Center gave me the medical structure and nutritional guidance I needed to transform my energy and health sustainably."
Media Host & Creator
Dual hormone activation provides synchronized control over appetite, glucose, and fat breakdown.
Signals the brain's satiety centers early during a meal, naturally reducing calorie intake without hunger pangs.
Targets both GIP and GLP-1 pathways to silence constant preoccupation with food and emotional eating triggers.
Improves how your body processes carbohydrates, reduces HbA1c, and promotes efficient metabolic fat utilization.
Monthly doctor reviews ensure slow, comfortable titration to your optimal therapeutic dose while minimizing side effects.
Real patient weight loss transformations with medically supervised Tirzepatide therapy at Nairobi Bariatric Center.
How Tirzepatide (dual hormone) compares with standard single-hormone GLP-1 therapy.
| Clinical Aspect | Tirzepatide (Dual-Agonist) | Semaglutide (GLP-1 Only) |
|---|---|---|
| Hormone Targets | Dual-Action: GLP-1 + GIP Receptors | Single-Action: GLP-1 Receptor Only |
| Weight Loss (Clinical Trials) | Up to 20–22% total body weight reduction | 10–15% total body weight reduction |
| Blood Sugar (HbA1c) Impact | Superior reduction in HbA1c and insulin sensitivity | Moderate to strong reduction in HbA1c |
| Craving & Satiety Control | Enhanced dual suppression of appetite and cravings | Effective, though some patients plateau over time |
| Side Effect Profile | Nausea, mild fatigue, manageable via titration | Similar GI profile; managed via titration |
| Availability at NBC | Available under doctor prescription and supervision | Available under doctor prescription and supervision |
Evaluating medical injectable therapy against surgical weight loss options.
| Feature | Injectable Medical Therapy | Bariatric Surgery |
|---|---|---|
| Average Weight Loss | Up to 20-22% (Tirzepatide), varies by adherence | 25–35% of total body weight (sustained) |
| Invasiveness | Non-surgical, painless subcutaneous weekly injection | Minimally invasive laparoscopic surgery (general anesthesia) |
| Recovery Time | Zero downtime — return to routine immediately | 2–4 weeks recovery, structured liquid diet transition |
| Long-Term Cost (5 Years) | Continuous treatment courses as needed | ~Ksh 1.78M one-time (procedure + supplements) |
| Best Suited For | BMI 27–40, surgery hesitation, or post-op regain | Severe obesity (BMI ≥40 or ≥35 with comorbidities) |
Common adjustments and expert tips to ensure maximum comfort throughout your course.
| Side Effect | Biological Reason | Clinical Management Tip |
|---|---|---|
| Nausea | Slowed gastric emptying keeps food in the stomach longer | Start on low dose; eat small, bland meals; avoid oily foods |
| Vomiting | Eating beyond fullness or too rapidly | Hydrate slowly; stop eating as soon as satiety is felt |
| Constipation | Reduced bowel motility from hormonal shifts | Increase water and fiber gradually; daily light walking |
| Diarrhea | Changes in digestive gut motility | Avoid high-fat foods; maintain electrolyte hydration |
| Bloating & Gas | Delayed digestion causing gut fermentation | Eat slowly; avoid carbonated drinks and gas-producing legumes |
| Fatigue | Lower calorie consumption and blood sugar adjustment | Ensure sufficient protein; rest as your metabolism adapts |
| Mild Dizziness | Hydration or blood sugar shifts early on | Hydrate well; avoid skipping meals; rise slowly from sitting |
| Hair Thinning | Rapid weight loss triggering temporary telogen effluvium | Ensure adequate protein, iron, and biotin supplements |
Treatment is prescription-only and strictly prohibited for pregnant/breastfeeding women, individuals with a personal or family history of medullary thyroid cancer (MTC), MEN2, or severe pancreatitis.
Doctor-led prescriptions by European-trained bariatric specialist Dr. Lydmila Shchukina
Holistic medical care: monthly doctor checks, nutrition planning, and psychotherapy
Proper injection training and genuine pharmaceutical supply chain verification
Psychological Correction of Eating Habits (PCEH) to prevent weight regain post-treatment
24/7 clinical support team and patient support group access
Over 20 years of dedicated bariatric and obesity treatment expertise in Kenya
Yes. Genuine dual-agonist therapies including Tirzepatide are available at Nairobi Bariatric Center, prescribed by licensed bariatric doctors following comprehensive clinical and medical evaluation.
Semaglutide targets only the GLP-1 receptor, while Tirzepatide is a dual-agonist targeting both GLP-1 and GIP receptors. In clinical studies, dual-agonist therapy demonstrated higher total weight loss (up to 20–22% vs 10–15%).
Treatment pricing is tailored to your required dosage progression, medication tier, and support package (including doctor reviews, dietetic care, and psychotherapy). Full investment details are discussed transparently during your specialist consultation.
No. These are potent prescription medications that must be evaluated and managed by a qualified doctor to ensure safe dosing, side effect prevention, and metabolic monitoring.
Appetite suppression is typically noticed within the first 1–2 weeks. Noticeable physical weight reduction begins around weeks 3–4, with consistent progress throughout the multi-month course.
Yes. Dual-agonist therapies are particularly beneficial for individuals with insulin resistance and PCOS because they improve metabolic sensitivity and regulate blood sugar alongside weight loss.
Experience next-generation dual-agonist medical weight loss. Meet Dr. Lydmila Shchukina to review your health markers, discuss dosage options, and tailor your treatment.
• Online Video Consult: Ksh. 2,000
• In-Person Clinic Consult: Ksh. 4,000
Please complete the details below to request a private consultation with our medical team.
